查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1771704

呼吸道融合細胞病毒疫苗市場規模、佔有率、趨勢分析報告：按類型、技術、目標人口、分銷管道、地區、細分市場、預測至 2025-2030 年

Respiratory Syncytial Virus Vaccines Market Size, Share & Trends Analysis Report By Type (Passive Immunization, Preventive Vaccines), By Technology, By Targeted Population, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

呼吸道融合細胞病毒(RSV) 疫苗市場成長與趨勢：

根據 Grand View Research, Inc. 的最新報告，全球呼吸道融合細胞病毒疫苗市場規模預計到 2030 年將達到 283.9 億美元，2025 年至 2030 年的複合年成長率為 42.17%。隨著人口老化和 COPD、氣喘和糖尿病等併發症變得越來越普遍，對疫苗接種等預防措施的需求只會增加。 RSV 疫苗在多個年齡層中的核准大大擴展了潛在市場。此外，越來越多的政府支持，包括公共疫苗宣傳活動，有助於推動疫苗接種和市場滲透。 RSV 越來越被認知到是全球重大的公共衛生威脅，凸顯了持續創新和投資該領域的重要性。

推動市場成長的關鍵因素是公共衛生當局擴大疫苗建議範圍。 2025 年 4 月，美國免疫實踐諮詢委員會 (ACIP) 決定向 50-59 歲患有嚴重 RSV 疾病風險較高的成年人推薦包括葛蘭素史克的 AREXVY 在內的 RSV 疫苗。這包括患有氣喘、慢性阻塞性肺病(COPD)、糖尿病、心臟病等慢性疾病的人以及長期照護機構的居民。這項建議建立在 ACIP 2024 年 6 月投票的基礎上，該投票建議所有 75 歲及以上的成年人以及 60-74 歲有潛在健康風險的成年人接種疫苗。此類政策擴展對於提高疫苗接種率和增加 AREXVY 等產品的商業性潛力至關重要，從而進一步刺激 RSV 疫苗市場。

技術創新和產品差異化也是塑造呼吸道合胞病毒（RSV）疫苗市場的關鍵力量。 mRNA 和佐劑疫苗平台的突破正在提升疫苗的有效性、安全性和給藥的便利性。例如，Moderna 的 mRNA 疫苗 mRESVIA 已於 2024 年 5 月核准，適用於 60 歲及以上成年人，這是該公司第二款獲得 FDA核准的mRNA 疫苗，展現了 mRNA 技術在感染疾病預防領域的強勁發展勢頭。葛蘭素史克的 AREXVY 利用佐劑配方來增強老年人，尤其是免疫力較弱的老年人的免疫反應。針對不同族群提供多種疫苗選擇將有助於促進競爭，同時擴大疫苗的可及性並增強市場對呼吸道合胞病毒疫苗有效性的信心。

公共和私營部門的投入不斷增加，加速了臨床試驗和監管核准的步伐。輝瑞、Moderna、葛蘭素史克和默克等大型製藥公司正積極透過大規模3期臨床試驗探索新的適應症和年齡層。輝瑞繼續將其呼吸道合胞病毒疫苗ABRYSVO推廣至更年輕的族群。預計這些進展將長期促進競爭、改善產品創新並降低成本，這對於維持長期市場成長至關重要，尤其是在新興經濟體。

此外，與全球衛生組織夥伴關係以及分級定價策略對於擴大中低收入國家呼吸道合胞病毒疫苗的可及性至關重要。隨著呼吸道合胞病毒的季節性和傳播模式因氣候變遷和全球流動性而發生變化，綜合監測和響應迅速的疫苗接種政策將變得越來越重要。隨著指南的不斷完善和強大的創新管道，呼吸道合胞病毒疫苗市場有望持續成長並對公共衛生產生積極影響。

呼吸道融合細胞病毒疫苗市場報告重點

  • 2024 年，被動免疫佔據主導地位，市場佔有率達 75.02%，主要得益於單株抗體 (mAb) 療法的進步。
  • 單株抗體 (mAb) 領域在 2024 年佔據了主導市場佔有率。 mAb 可提供即時被動免疫，因此是保護新生兒和免疫力缺乏患者等高風險族群的理想選擇。
  • 由於嬰兒和兒童疾病負擔較重以及近期預防方面的突破，預計到 2024 年將佔據最大的市場佔有率，達到 75.02%。 RSV 是全球嬰兒和兒童住院的主要原因，因此迫切需要有效的預防措施。
  • 受需求成長、疫苗供應增加和疫苗接種計畫擴大的推動，預計到 2024 年，醫院和零售藥局將佔據 53.68% 的市場佔有率。
  • 由於 RSV感染疾病率高且醫療保健基礎設施先進，北美在全球 RSV 疫苗市場佔有很大佔有率。
  • 全球RSV疫苗市場競爭激烈，阿斯特捷利康、賽諾菲、葛蘭素史克、輝瑞、Moderna、Icosavax、Meissa Vaccines、Codagenix、藍湖生物技術、默克等主要企業均專注於疫苗強化。

目錄

第1章調查方法與範圍

第2章執行摘要

3. RSV呼吸道融合細胞病毒市場變數、趨勢和範圍

  • 市場介紹/電網展望
  • 市場規模和成長前景
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 呼吸道融合細胞病毒（RSV）疫苗市場分析工具
    • 波特分析
    • PESTEL分析

第4章市場：類型評估與趨勢分析

  • 細分儀表板
  • 市場：2024 年和 2030 年類型變化分析
  • 被動免疫
  • 預防性疫苗

第5章 市場：技術評估/趨勢分析

  • 細分儀表板
  • 市場：2024 年和 2030 年技術變革分析
  • 單株抗體
  • 重組蛋白+佐劑
  • 基於mRNA的疫苗
  • 類病毒顆粒（VLP）

第6章 市場：目標人口估算與趨勢分析

  • 細分儀表板
  • 市場：2024 年和 2030 年目標人口變化分析
  • 成人
  • 嬰兒

第7章市場：通路評估及趨勢分析

  • 細分儀表板
  • 市場：2024 年和 2030 年分銷通路變化分析
  • 醫院和藥房
  • 政府供應商
  • 其他

第 8 章市場：區域評估/趨勢分析

  • 2024 年及 2030 年各地區市場佔有率
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第9章 競爭態勢

  • 主要市場參與企業的近期趨勢和影響分析
  • 公司分類
  • 公司熱圖分析
  • 公司簡介
    • AstraZeneca
    • Sanofi
    • GSK
    • Pfizer Inc.
    • Moderna
    • Icosavax
    • Meissa Vaccines
    • Codagenix
    • Blue Lake Biotechnology
    • Merck &Co., Inc.
Product Code: GVR-4-68040-625-1

RSV Vaccines Market Growth & Trends:

The global respiratory syncytial virusvaccines market size is expected to reach USD 28.39 billion by 2030, registering a CAGR of 42.17% from 2025 to 2030, according to a new report by Grand View Research, Inc. As populations age and comorbidities such as COPD, asthma, and diabetes become more prevalent, the demand for preventive measures like vaccination continues to rise. Regulatory approvals of RSV vaccines across multiple age groups have significantly expanded the addressable market. Furthermore, growing government support, including public immunization campaigns, has helped boost vaccination uptake and market penetration. The increasing global recognition of RSV as a serious public health threat underlines the importance of continued innovation and investment in this sector.

A key factor propelling market growth is the expansion of vaccine recommendations by public health authorities. In April 2025, the U.S. Advisory Committee on Immunization Practices (ACIP) voted to recommend RSV vaccines, including GSK's AREXVY, for adults aged 50-59 who are at elevated risk of severe RSV disease. This includes individuals with chronic conditions such as asthma, chronic obstructive pulmonary disease (COPD), diabetes, heart disease, and those residing in long-term care facilities. This recommendation builds upon ACIP's earlier vote in June 2024 to advise vaccination for all adults aged 75 and older, and for those aged 60-74 with underlying health risks. These policy expansions are critical in driving vaccine coverage and boosting the commercial viability of products like AREXVY, further energizing the RSV vaccine market.

Technological innovation and product differentiation are also vital forces shaping the RSV vaccine landscape. Breakthroughs in mRNA and adjuvanted vaccine platforms have improved efficacy, safety profiles, and delivery convenience. For example, Moderna's mRESVIA, approved in May 2024 for adults aged 60 and older, represents the company's second FDA-approved mRNA vaccine and highlights the momentum of mRNA technologies in infectious disease prevention. GSK's AREXVY leverages an adjuvanted formulation to enhance immune response in older adults, especially those with weakened immune systems. The availability of multiple vaccine options tailored to different population segments supports competition while broadening access and boosting market confidence in RSV vaccine efficacy.

Increased investments from both public and private sectors are accelerating the pace of clinical trials and regulatory approvals. Major pharmaceutical companies such as Pfizer, Moderna, GSK, and Merck are actively pursuing new indications and age groups through extensive Phase 3 trials. Pfizer continues to expand its RSV vaccine ABRYSVO into younger adult age groups. These developments are expected to intensify competition, improve product innovation, and lower costs over time, which is crucial for sustaining long-term market growth, particularly in emerging economies.

Additionally, partnerships with global health organizations and tiered pricing strategies will be key in expanding RSV vaccine access across low- and middle-income countries. As climate change and global mobility contribute to changes in RSV seasonality and transmission patterns, integrated surveillance and responsive vaccination policies will be increasingly important. With expanding recommendations and a strong innovation pipeline, the RSV vaccine market is poised for continued growth and public health impact.

Respiratory Syncytial Virus Vaccines Market Report Highlights:

  • In 2024, passive immunization led the market with a market share of 75.02%, primarily driven by advancements in monoclonal antibody (mAb) therapies.
  • The monoclonal antibodies (mAbs) segment secured the dominant market share in 2024. mAbs offer immediate passive immunity, making them ideal for protecting high-risk populations such as newborns and immunocompromised individuals.
  • The infants and children held the largest market share of 75.02% in 2024, due to the high disease burden and recent preventive breakthroughs. RSV is the leading cause of hospitalization in infants globally, prompting urgent demand for effective protective measures.
  • Hospital & retail pharmacies are expected to dominate the market in 2024 with share of 53.68% fueled by rising demand, vaccine accessibility, and expanding immunization programs.
  • North America holds a substantial share of the global RSV vaccine market, attributed to the high prevalence of RSV infections and advanced healthcare infrastructure.
  • The global RSV vaccines market is highly competitive, with key players such as AstraZeneca, Sanofi, GSK, Pfizer, Moderna, Icosavax, Meissa Vaccines, Codagenix, Blue Lake Biotechnology, and Merck, focusing on enhancing the vaccine.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. RSV (Respiratory Syncytial Virus) Vaccines Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. RSV (Respiratory Syncytial Virus) Vaccines Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. RSV (Respiratory Syncytial Virus) Vaccines Market: Type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. RSV (Respiratory Syncytial Virus) Vaccines Market: Type Movement Analysis, 2024 & 2030 (USD Million)
  • 4.3. Passive Immunization
    • 4.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Preventive Vaccines
    • 4.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. RSV (Respiratory Syncytial Virus) Vaccines Market: Technology Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. RSV (Respiratory Syncytial Virus) Vaccines Market: Technology Movement Analysis, 2024 & 2030 (USD Million)
  • 5.3. Monoclonal Antibodies
    • 5.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Recombinant Protein + Adjuvant
    • 5.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. mRNA-Based Vaccine
    • 5.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Virus-Like Particle (VLP)
    • 5.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. RSV (Respiratory Syncytial Virus) Vaccines Market: Targeted Population Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. RSV (Respiratory Syncytial Virus) Vaccines Market: Targeted Population Movement Analysis, 2024 & 2030 (USD Million)
  • 6.3. Adults
    • 6.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Infants and children
    • 6.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. RSV (Respiratory Syncytial Virus) Vaccines Market: Distribution Channel Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. RSV (Respiratory Syncytial Virus) Vaccines Market: Distribution Channel Movement Analysis, 2024 & 2030 (USD Million)
  • 7.3. Hospital & Retail Pharmacies
    • 7.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Government Suppliers
    • 7.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Others
    • 7.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. RSV (Respiratory Syncytial Virus) Vaccines Market: Regional Estimates & Trend Analysis

  • 8.1. RSV (Respiratory Syncytial Virus) Vaccines Market Share, By Region, 2024 & 2030 (USD Million)
  • 8.2. North America
    • 8.2.1. North America RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.2. U.S.
      • 8.2.2.1. U.S. RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.3. Canada
      • 8.2.3.1. Canada RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.4. Mexico
      • 8.2.4.1. Mexico RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3. Europe
    • 8.3.1. Europe RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.2. UK
      • 8.3.2.1. UK RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.3. Germany
      • 8.3.3.1. Germany RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.4. France
      • 8.3.4.1. France RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.5. Italy
      • 8.3.5.1. Italy RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.6. Spain
      • 8.3.6.1. Spain RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.7. Denmark
      • 8.3.7.1. Denmark RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.8. Sweden
      • 8.3.8.1. Sweden RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.9. Norway
      • 8.3.9.1. Norway RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4. Asia Pacific
    • 8.4.1. Asia Pacific RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.2. Japan
      • 8.4.2.1. Japan RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.3. China
      • 8.4.3.1. China RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.4. India
      • 8.4.4.1. India RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.5. Australia
      • 8.4.5.1. Australia RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.6. South Korea
      • 8.4.6.1. South Korea RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.7. Thailand
      • 8.4.7.1. Thailand RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5. Latin America
    • 8.5.1. Latin America RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.2. Brazil
      • 8.5.2.1. Brazil RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.3. Argentina
      • 8.5.3.1. Argentina RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6. Middle East and Africa
    • 8.6.1. Middle East and Africa RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.2. South Africa
      • 8.6.2.1. South Africa RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.3. Saudi Arabia
      • 8.6.3.1. South Africa RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.4. UAE
      • 8.6.4.1. UAE RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.5. Kuwait
      • 8.6.5.1. Kuwait RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis by Key Market Participants
  • 9.2. Company Categorization
  • 9.3. Company Heat Map Analysis
  • 9.4. Company Profiles
    • 9.4.1. AstraZeneca
      • 9.4.1.1. Participant's Overview
      • 9.4.1.2. Financial Performance
      • 9.4.1.3. Product Benchmarking
      • 9.4.1.4. Recent Developments/ Strategic Initiatives
    • 9.4.2. Sanofi
      • 9.4.2.1. Participant's Overview
      • 9.4.2.2. Financial Performance
      • 9.4.2.3. Product Benchmarking
      • 9.4.2.4. Recent Developments/ Strategic Initiatives
    • 9.4.3. GSK
      • 9.4.3.1. Participant's Overview
      • 9.4.3.2. Financial Performance
      • 9.4.3.3. Product Benchmarking
      • 9.4.3.4. Recent Developments/ Strategic Initiatives
    • 9.4.4. Pfizer Inc.
      • 9.4.4.1. Participant's Overview
      • 9.4.4.2. Financial Performance
      • 9.4.4.3. Product Benchmarking
      • 9.4.4.4. Recent Developments/ Strategic Initiatives
    • 9.4.5. Moderna
      • 9.4.5.1. Participant's Overview
      • 9.4.5.2. Financial Performance
      • 9.4.5.3. Product Benchmarking
      • 9.4.5.4. Recent Developments/ Strategic Initiatives
    • 9.4.6. Icosavax
      • 9.4.6.1. Financial Performance
      • 9.4.6.2. Product Benchmarking
      • 9.4.6.3. Recent Developments/ Strategic Initiatives
    • 9.4.7. Meissa Vaccines
      • 9.4.7.1. Participant's Overview
      • 9.4.7.2. Financial Performance
      • 9.4.7.3. Product Benchmarking
      • 9.4.7.4. Recent Developments/ Strategic Initiatives
    • 9.4.8. Codagenix
      • 9.4.8.1. Participant's Overview
      • 9.4.8.2. Financial Performance
      • 9.4.8.3. Product Benchmarking
      • 9.4.8.4. Recent Developments/ Strategic Initiatives
    • 9.4.9. Blue Lake Biotechnology
      • 9.4.9.1. Participant's Overview
      • 9.4.9.2. Financial Performance
      • 9.4.9.3. Product Benchmarking
      • 9.4.9.4. Recent Developments/ Strategic Initiatives
    • 9.4.10. Merck & Co., Inc.
      • 9.4.10.1. Participant's Overview
      • 9.4.10.2. Financial Performance
      • 9.4.10.3. Product Benchmarking
      • 9.4.10.4. Recent Developments/ Strategic Initiatives

List of Tables

  • Table 1. List of abbreviation
  • Table 2. Global RSV (Respiratory Syncytial Virus) vaccines market, by region, 2018 - 2030 (USD Million)
  • Table 3. Global RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 4. Global RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 5. Global RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 6. Global RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 7. North America RSV (Respiratory Syncytial Virus) vaccines market, by country, 2018 - 2030 (USD Million)
  • Table 8. North America RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 9. North America RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 10. North America RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 11. North America RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 12. U.S. RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 13. U.S. RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 14. U.S. RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 15. U.S. RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 16. Canada RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 17. Canada RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 18. Canada RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 19. Canada RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 20. Mexico RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 21. Mexico RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 22. Mexico RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 23. Mexico RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 24. Europe RSV (Respiratory Syncytial Virus) vaccines market, by country, 2018 - 2030 (USD Million)
  • Table 25. Europe RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 26. Europe RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 27. Europe RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 28. Europe RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 29. UK RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 30. UK RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 31. UK RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 32. UK RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 33. Germany RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 34. Germany RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 35. Germany RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 36. Germany RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 37. France RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 38. France RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 39. France RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 40. France RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 41. Italy RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 42. Italy RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 43. Italy RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 44. Italy RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 45. Spain RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 46. Spain RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 47. Spain RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 48. Spain RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 49. Denmark RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 50. Denmark RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 51. Denmark RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 52. Denmark RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 53. Sweden RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 54. Sweden RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 55. Sweden RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 56. Sweden RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 57. Norway RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 58. Norway RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 59. Norway RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 60. Norway RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 61. Asia Pacific RSV (Respiratory Syncytial Virus) vaccines market, by country, 2018 - 2030 (USD Million)
  • Table 62. Asia Pacific RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 63. Asia Pacific RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 64. Asia Pacific RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 65. Asia Pacific RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 66. Japan RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 67. Japan RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 68. Japan RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 69. Japan RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 70. China RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 71. China RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 72. China RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 73. China RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 74. India RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 75. India RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 76. India RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 77. India RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 78. Australia RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 79. Australia RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 80. Australia RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 81. Australia RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 82. South Korea RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 83. South Korea RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 84. South Korea RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 85. South Korea RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 86. Thailand RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 87. Thailand RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 88. Thailand RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 89. Thailand RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 90. Latin America RSV (Respiratory Syncytial Virus) vaccines market, by country, 2018 - 2030 (USD Million)
  • Table 91. Latin America RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 92. Latin America RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 93. Latin America RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 94. Latin America RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 95. Brazil RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 96. Brazil RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 97. Brazil RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 98. Brazil RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 99. Argentina RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 100. Argentina RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 101. Argentina RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 102. Argentina RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 103. MEA RSV (Respiratory Syncytial Virus) vaccines market, by country, 2018 - 2030 (USD Million)
  • Table 104. MEA RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 105. MEA RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 106. MEA RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 107. MEA RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 108. South Africa RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 109. South Africa RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 110. South Africa RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 111. South Africa RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 112. Saudi Arabia RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 113. Saudi Arabia RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 114. Saudi Arabia RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 115. Saudi Arabia RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 116. UAE RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 117. UAE RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 118. UAE RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 119. UAE RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 120. Kuwait RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 121. Kuwait RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 122. Kuwait RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 123. Kuwait RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 RSV (Respiratory Syncytial Virus) vaccines market segmentation
  • Fig. 2 Data analysis models
  • Fig. 3 Market formulation and validation
  • Fig. 4 Data validating & publishing
  • Fig. 5 Market research process
  • Fig. 6 Information procurement
  • Fig. 7 Primary research
  • Fig. 8 Value-chain-based sizing & forecasting
  • Fig. 9 QFD modelling for market share assessment
  • Fig. 10 Market formulation & validation
  • Fig. 11 Commodity flow analysis
  • Fig. 12 Market outlook
  • Fig. 13 Segment snapshot-1
  • Fig. 14 Segment snapshot-2
  • Fig. 15 Competitive landscape snapshot
  • Fig. 16 Market trends & outlook
  • Fig. 17 Porter's five force analysis
  • Fig. 18 PESTEL analysis
  • Fig. 19 RSV (Respiratory Syncytial Virus) vaccines market: Product outlook key takeaways
  • Fig. 20 RSV (Respiratory Syncytial Virus) vaccines market: Type movement analysis
  • Fig. 21 Passive immunization market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Preventive vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 RSV (Respiratory Syncytial Virus) vaccines market: Technology outlook key takeaways
  • Fig. 24 RSV (Respiratory Syncytial Virus) vaccines market: Technology movement analysis
  • Fig. 25 Monoclonal antibodies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Recombinant Protein + Adjuvant market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 mRNA-based vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 RSV (Respiratory Syncytial Virus) vaccines market: Targeted Population outlook key takeaways
  • Fig. 29 RSV (Respiratory Syncytial Virus) vaccines market: Targeted Population movement analysis
  • Fig. 30 Adults market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Infants and children market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 RSV (Respiratory Syncytial Virus) vaccines market: Distribution Channel outlook key takeaways
  • Fig. 33 RSV (Respiratory Syncytial Virus) vaccines market: Distribution Channel movement analysis
  • Fig. 34 Hospital & retail pharmacies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Government suppliers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Regional marketplace outlook, 2024 & 2030 (USD million)
  • Fig. 38 Regional marketplace: Key takeaways
  • Fig. 39 North America RSV (Respiratory Syncytial Virus) vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Key country dynamics
  • Fig. 41 US RSV (Respiratory Syncytial Virus) vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Key country dynamics
  • Fig. 43 Canada RSV (Respiratory Syncytial Virus) vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Key country dynamics
  • Fig. 45 Mexico RSV (Respiratory Syncytial Virus) vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Europe RSV (Respiratory Syncytial Virus) vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Key country dynamics
  • Fig. 48 UK RSV (Respiratory Syncytial Virus) vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Key country dynamics
  • Fig. 50 Germany RSV (Respiratory Syncytial Virus) vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Key country dynamics
  • Fig. 52 France RSV (Respiratory Syncytial Virus) vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Key country dynamics
  • Fig. 54 Spain RSV (Respiratory Syncytial Virus) vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Key country dynamics
  • Fig. 56 Italy RSV (Respiratory Syncytial Virus) vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Key country dynamics
  • Fig. 58 Denmark RSV (Respiratory Syncytial Virus) vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Key country dynamics
  • Fig. 60 Sweden RSV (Respiratory Syncytial Virus) vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Key country dynamics
  • Fig. 62 Norway RSV (Respiratory Syncytial Virus) vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Asia Pacific RSV (Respiratory Syncytial Virus) vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Key country dynamics
  • Fig. 65 Japan RSV (Respiratory Syncytial Virus) vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 Key country dynamics
  • Fig. 67 China RSV (Respiratory Syncytial Virus) vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 Key country dynamics
  • Fig. 69 India RSV (Respiratory Syncytial Virus) vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 Key country dynamics
  • Fig. 71 Australia RSV (Respiratory Syncytial Virus) vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 Key country dynamics
  • Fig. 73 South Korea RSV (Respiratory Syncytial Virus) vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 Key country dynamics
  • Fig. 75 Thailand RSV (Respiratory Syncytial Virus) vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 Key country dynamics
  • Fig. 77 Market participant categorization
  • Fig. 78 RSV (Respiratory Syncytial Virus) vaccines market position analysis, 2024
  • Fig. 79 Strategic framework